



MEDICAL POLICY

MEDICAL POLICY DETAILS	
Medical Policy Title	EXTRACORPOREAL SHOCK WAVE THERAPY (ESWT) FOR MUSCULOSKELETAL CONDITIONS AND SOFT TISSUE WOUNDS
Policy Number	2.01.31
Category	Technology Assessment
Effective Date	10/18/01
Revised Date	02/21/02, 02/20/03, 02/19/04, 02/17/05, 12/15/05, 01/18/07, 10/18/07, 09/18/08, 08/20/09, 07/15/10, 06/16/11, 06/21/12, 08/15/13, 07/17/14, 06/18/15, 06/16/16, 06/15/17, 06/21/18, 05/16/19, 03/19/20
Product Disclaimer	<ul style="list-style-type: none"> • If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. • If a commercial product (including an Essential Plan product) or a Medicaid product covers a specific service, medical policy criteria apply to the benefit. • If a Medicare product covers a specific service, and there is no national or local Medicare coverage decision for the service, medical policy criteria apply to the benefit.

POLICY STATEMENT

- I. Based upon our criteria and the assessment of peer-reviewed literature, extracorporeal shock wave therapy (ESWT) for the treatment of musculoskeletal conditions, including, but not limited to, chronic plantar fasciitis, tendonitis of the shoulder and elbow, and non-union of fractures, has not been medically proven to be effective and, therefore, is considered **investigational**.
- II. Based upon our criteria and the assessment of peer-reviewed literature, ESWT as a treatment for wound-healing has not been medically proven to be effective and, therefore, is considered **investigational**.

Refer to Corporate Medical Policy #11.01.03 Experimental and Investigational Services.

POLICY GUIDELINES

The Federal Employee Health Benefit Program (FEHBP/FEP) requires that procedures, devices or laboratory tests approved by the U.S. Food and Drug Administration (FDA) may not be considered investigational and, thus, these procedures, devices or laboratory tests may be assessed only on the basis of their medical necessity.

DESCRIPTION

ESWT is proposed as a non-surgical treatment option for musculoskeletal conditions, including chronic plantar fasciitis and tendonitis of the shoulder and elbow, as well as for non-union of fractures. The mechanism by which ESWT achieves a therapeutic intervention in orthopedic conditions is not completely understood, but there are several hypotheses. ESWT may disrupt fibrous tissue, allowing for the subsequent promotion of revascularization and healing of tissue. Also, it is believed that the direct and indirect effects of the shock waves may damage cell membranes, so that nociceptors cannot build up a potential to transmit pain signals. Chronic conditions such as tendinitis can be associated with a substantial degree of scarring and calcium deposition. Calcific deposits may restrict motion and encroach on nerves and blood vessels, causing pain and dysfunction. It is thought that the shock waves will break up these deposits, loosen structures, and promote resorption of calcium, thereby decreasing pain and improving function.

Both high-dose and low-dose focused ESWT have been utilized. A high-dose protocol consists of a single treatment of high-energy shock waves (1300mJ/mm²). This painful procedure requires anesthesia. A low-dose protocol consists of multiple treatments, spaced one week to one month apart, in which a lower dose of shock waves is applied. This protocol does not require anesthesia.

Medical Policy: EXTRACORPOREAL SHOCK WAVE THERAPY (ESWT) FOR MUSCULOSKELETAL CONDITIONS AND SOFT TISSUE WOUNDS

Policy Number: 2.01.31

Page: 2 of 8

Another type of ESWT is under investigation. Radial ESWT is generated ballistically by accelerating a bullet to hit an applicator, which transforms the kinetic energy into radially expanding shock waves. Other types of ESWT produce focused shock waves that show deeper tissue penetration, with significantly higher energies concentrated to a small focus. Radial ESWT is described as an alternative to focused ESWT and is said to address larger treatment areas, thus providing potential advantages in superficial applications like tendinopathies.

ESWT is being proposed as a new approach to soft tissue wound-healing. It is being studied as a treatment for delayed or chronic, non-healing wounds and also as a therapy to accelerate tissue repair in wounds such as diabetic ulcers and burns. Although the precise mechanism by which ESWT could provide a therapeutic effect is not known, it is thought that ESWT may decrease inflammation and induce neovascularization, allowing for improved perfusion and accelerated epithelialization.

RATIONALE

The OssaTron® device (Health Tronics) was approved by the FDA in July 2000 for chronic proximal plantar fasciitis and is also approved for use in the treatment of lateral epicondylitis. Dornier MedTech, Inc. received FDA premarket approval for Epos Ultra® extracorporeal shock wave therapy device on January 15, 2002 for the treatment of plantar fasciitis. Siemens' SONOCUR® Basic System was approved in July 2002 for treatment of epicondylitis (tennis elbow). Orthometrix's Orbasone™ Pain relief System and Medispec's Orthospec™, received FDA premarket approval in 2005; both are approved to treat plantar fasciitis. The FDA-labeled indication for the OssaTron® and Epos Ultra® device specifically describes a high-dose protocol, while the labeled indication for the SONOCUR® device describes a low-dose protocol. Radial ESWT (rESWT) received pre-market approval (PMA) in May 2007. The FDA-approved device is the Dolorclast® from EMS Electro Medical Systems, Nyon, Switzerland.

There is insufficient data published in the peer-reviewed literature to draw conclusions about the effectiveness of either focused or radial ESWT for treatment of musculoskeletal conditions. Outcomes of trials on clinically relevant measures are inconsistent, and interpretation is complicated by variations in treatment protocols. Published evidence for the use of ESWT to promote healing of fracture non-union consists of several relatively small RCTs with methodologic limitations, along with reports of case series, and it cannot be concluded from such studies that ESWT results in acceleration of union. Small RCTs have reported a benefit for pain and functional outcomes for tendinopathies, including shoulder and Achilles tendinopathies; however, many trials have been considered poor quality. More high-quality trials are needed to determine whether ESWT improves outcomes.

Likewise, the available evidence in the medical literature evaluating the safety and efficacy of ESWT for wound-healing is insufficient to support its use for this indication at the present time. The Sanuwave Health dermaPACE® system received FDA clearance on December 28, 2017. This device provides acoustic pressure shockwaves in the treatment of chronic, full-thickness diabetic foot ulcers with wound areas measuring no larger than 16 cm², which extend through the epidermis, dermis, tendon, or capsule, but without bone exposure. The dermaPACE System is indicated for adult (aged 22 years and older) diabetic patients presenting with diabetic foot ulcers greater than 30 days in duration, and is indicated for use in conjunction with standard diabetic ulcer care. The FDA reviewed clinical data from two multi-center, randomized, double-blind studies with a total of 336 diabetic patients receiving either usual care plus the dermaPACE System shockwave therapy or usual care plus sham shockwave therapy. In the first study, 206 subjects were randomized to either dermaPACE® (n=107) or to sham-controls (n=99). At the 24-week endpoint, the rate of wound closure in the dermaPACE® cohort was 39.3%, compared to 26.3% in the control group. In the second study, 130 subjects were randomized to dermaPACE® (n=65) or sham-controls (n=65). At the 24-week endpoint, the rate of wound closure in the dermaPACE® cohort was 35.4%, compared to 26.2% in the control group.

CODES

- *Eligibility for reimbursement is based upon the benefits set forth in the member's subscriber contract.*
- **CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.**
- *Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.*

Medical Policy: EXTRACORPOREAL SHOCK WAVE THERAPY (ESWT) FOR MUSCULOSKELETAL CONDITIONS AND SOFT TISSUE WOUNDS

Policy Number: 2.01.31

Page: 3 of 8

- *Code Key: Experimental/Investigational = (E/I), Not medically necessary/ appropriate = (NMN).*

CPT Codes

Code	Description
0101T (E/I)	Extracorporeal shock wave involving musculoskeletal system, not otherwise specified, high energy
0102T (E/I)	Extracorporeal shock wave, high energy, performed by a physician, requiring anesthesia other than local, involving lateral humeral epicondyle
0512T (E/I)	Extracorporeal shock wave for integumentary wound healing, high energy, including topical application and dressing care; initial wound
0513T (E/I)	each additional wound (List separately in addition to code for primary procedure)
28890 (E/I)	Extracorporeal shock wave, high energy, performed by a physician or other qualified health care professional, requiring anesthesia other than local, including ultrasound guidance, involving the plantar fascia

Copyright © 2020 American Medical Association, Chicago, IL

HCPCS Codes

Code	Description
No specific code(s)	

ICD10 Codes

Code	Description
G56.00-G56.03	Carpal tunnel syndrome (code range)
M72.2	Plantar fascial fibromatosis
M75.00-M75.02	Adhesive capsulitis of shoulder (code range)
M75.20-M75.22	Bicipital tendinitis (code range)
M75.30-M75.32	Calcific tendinitis of shoulder (code range)
M77.00-M77.02	Medial epicondylitis (code range)
M77.10-M77.12	Lateral epicondylitis, elbow (code range)
M77.30-M77.32	Calcaneal spur, foot (code range)
M87.0514-M87.059	Idiopathic aseptic necrosis of femur (code range)
Multiple ICD10 diagnosis codes for open wounds, burns, and fracture nonunion codes	

REFERENCES

Ahadi T, et al. Prolotherapy vs radial extracorporeal shock wave therapy in the short-term treatment of lateral epicondylitis: a randomized clinical trial. Pain Med 2019 Jan 29. [Epub ahead of print]

*Alves EM, et al. The use of extracorporeal shock waves in the treatment of osteonecrosis of the femoral head: a systematic review. Clin Rheumatol 2009 Nov;28(11):1247-1251.

Aydın A and Atıç R. Comparison of extracorporeal shock-wave therapy and wrist extensor splint application in the treatment of lateral epicondylitis: a prospective randomized controlled study. J Pain Res 2018 Aug 2;11:1459-1467.

Babatunde OO, et al. Comparative effectiveness of treatment options for plantar heel pain: a systematic review with network meta-analysis. Br J Sports Med 2019 Feb;53(3):182-194.

Medical Policy: EXTRACORPOREAL SHOCK WAVE THERAPY (ESWT) FOR MUSCULOSKELETAL CONDITIONS AND SOFT TISSUE WOUNDS

Policy Number: 2.01.31

Page: 4 of 8

*Baccaglioni W, et al. The role of the low-intensity extracorporeal shockwave therapy on penile rehabilitation after radical prostatectomy: a randomized clinical trial. J Sex Med 2020 Jan 29. [Epub ahead of print]

Beyazel MS, et al. Comparison of the effectiveness of local corticosteroid injection and extracorporeal shock wave therapy in patients with lateral epicondylitis. J Phys Ther Sci 2015 Dec;27(12):3755-8.

BlueCross BlueShield Association. Extracorporeal shock wave treatment for plantar fasciitis and other musculoskeletal conditions. Medical Policy Reference Manual Policy #2.01.40. 2019 June 13.

*BlueCross BlueShield Technology Evaluation Center. Extracorporeal Shock Wave Therapy (ESWT) for musculoskeletal conditions. 2003 Aug;18(5):1-42.

Brunckhorst O, et al. A systematic review of the long-term efficacy of low-intensity shockwave therapy for vasculogenic erectile dysfunction. Int Urol Nephrol 2019 May;51(5):773-781.

*Buchbinder R, et al. Systematic review of the efficacy and safety of shock wave therapy for lateral elbow pain. J Rheum 2006;33(7):1351-63.

Butterworth PA, et al. The effectiveness of extracorporeal shock wave therapy for the treatment of lower limb ulceration: a systematic review. J Foot Ankle Res 2015 Feb 5;8:3.

*Cacchio A, et al. Extracorporeal shock-wave therapy compared with surgery for hypertrophic long-bone unions. J Bone Joint Surg Am 2009 Nov;91(11):2589-97.

Carlisi E, et al. Focused extracorporeal shock wave therapy for greater trochanteric pain syndrome with gluteal tendinopathy: a randomized controlled trial. Clin Rehabil 2019 Apr;33(4):670-680.

Carulli C, et al. Effectiveness of extracorporeal shockwave therapy in three major tendon diseases. J Orthop Traumatol 2016 March;17(1):15-20.

*Chen JM, et al. Functional outcomes of bilateral hip necrosis: total hip arthroplasty versus extracorporeal shockwave. Arch Orthop Trauma Surg 2009 Jun;129(6):837-41.

*Chuckpaiwong B, et al. Extracorporeal shock wave for chronic proximal plantar fasciitis: 225 patients with results and outcome predictors. J Foot Ankle Surg 2009 Mar-Apr;48(2):148-55.

Cooper B and Bachoo P. Extracorporeal shock wave therapy for the healing and management of venous leg ulcers. Cochrane Database Syst Rev. 2018 Jun 11;6:CD011842.

Di Mauro M, et al. Extracorporeal shock wave therapy in Peyronie's disease: Clinical efficacy and safety from a single-arm observational study. World J Mens Health 2019 Sep;37(3):339-346.

*Furia JP. High-energy extracorporeal shock wave therapy as a treatment for insertional Achilles tendinopathy. A J Sports Med 2006;34(5):733-40.

*Furia JP, et al. Low-energy extracorporeal shock wave therapy as treatment for greater trochanteric pain syndrome. Am J Sports Med 2009 Sep;37(9):1806-13.

*Gerdesmayer L, et al. Radial extracorporeal shock wave therapy is a safe and effective in the treatment of chronic recalcitrant plantar fasciitis: results of a confirmatory randomized placebo-controlled multicenter study. Am J Sports Med 2008 Nov;36(11):2100-9.

*Gollwitzer H, et al. Extracorporeal shock wave therapy for chronic painful heel syndrome: a prospective, double blind, randomized trial assessing the efficacy of a new electromagnetic shock wave device. J Foot Ankle Surg 2007 Sep-Oct;46(5):348-57.

Gollwitzer H, et al. Clinically relevant effectiveness of focused extracorporeal shock wave therapy in the treatment of chronic plantar fasciitis: a randomized, controlled multicenter study. J Bone Joint Surg Am 2015 May 6;97(9):701-8.

Medical Policy: EXTRACORPOREAL SHOCK WAVE THERAPY (ESWT) FOR MUSCULOSKELETAL CONDITIONS AND SOFT TISSUE WOUNDS

Policy Number: 2.01.31

Page: 5 of 8

- *Greve JM, et al. Comparison of radial shockwaves and conventional physiotherapy for treating plantar fasciitis. Clinics 2009;64(2):97-103.
- Guler NS, et al. Efficacy of extracorporeal shockwave therapy in patients with lateral epicondylitis: a randomized, placebo-controlled, double-blind clinical trial. North Clin Istanb 2018 Dec 3;5(4):314-318.
- *Haake M, et al. Extracorporeal shock wave therapy for plantar fasciitis: randomised controlled multicentre trial. Brit Med J 2003 Jul;327(7406):75-7.
- Hao Y, et al. Meta-analysis of the potential role of extracorporeal shockwave therapy in osteonecrosis of the femoral head. J Orthop Surg Res 2018 Jul 3;13(1):166.
- *Hearnden A, et al. Extracorporeal shock wave therapy in chronic calcific tendinitis of the shoulder- is it effective? Acta Orthop Belg 2009 Feb;75(1):25-31.
- Hitchman LH, et al. Extracorporeal shockwave therapy for diabetic foot ulcers: a systematic review and meta-analysis. Ann Vasc Surg 2018 Nov 26. [Epub ahead of print]
- *Ho C. Extracorporeal shock wave treatment for chronic lateral epicondylitis (tennis elbow). Issues Emerg Health Technol 2007 Jan;(96 part 2):1-4.
- Hsiao MY, et al. Comparative effectiveness of autologous blood-derived products, shock-wave therapy and corticosteroids for treatment of plantar fasciitis: a network meta-analysis. Rheumatology 2015 Sep;54(9):1735-43.
- *Huisstede BM, et al. Evidence for effectiveness of extracorporeal shockwave therapy (ESWT) to treat calcific and non-calcific rotator cuff tendinosis- a systematic review. Man Ther 2011 Oct;16(5):419-33.
- *Institute for Clinical Systems Improvement. Technology assessment report: extracorporeal shock wave therapy for plantar fasciitis. TA #86. 2004 Nov.
- Ioppolo F, et al. Comparison between extracorporeal shock wave therapy and intra-articular hyaluronic acid injections in the treatment of first carpometacarpal joint osteoarthritis. Ann Rehabil Med 2018 Feb;42(1):92-100.
- Kim JC, et al. Effect of extracorporeal shockwave therapy on carpal tunnel syndrome: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) 2019 Aug;98(33):e16870.
- *Kudo P, et al. Randomized, placebo-controlled, double-blind clinical trial evaluating the treatment of plantar fasciitis with an extracorporeal shockwave therapy (ESWT) device; a north American confirmatory study. J Ortho Res 2006 Feb;24(2):115-23.
- Lai TW, et al. Ultrasonography and clinical outcome comparison of extracorporeal shock wave therapy and corticosteroid injections for chronic plantar fasciitis: a randomized controlled trial. J Musculoskelet Neuronal Interact 2018 Mar 1;18(1):47-54.
- Li G, et al. Effects of radial extracorporeal shockwave therapy on spasticity of upper-limb agonist/antagonist muscles in patients affected by stroke: a randomized, single-blind clinical trial. Age Ageing 2019 Dec 17. [Epub ahead of print]
- Li H, et al. Comparison of efficacy of eight treatments for plantar fasciitis: A network meta-analysis. J Cell Physiol 2018 Jan;234(1):860-870.
- Li S, et al. Clinical effects of extracorporeal shock-wave therapy and ultrasound-guided local corticosteroid injections for plantar fasciitis in adults: a meta-analysis of randomized controlled trials. Medicine (Baltimore) 2018 Dec;97(50):e13687.
- Li T, et al. Application and efficacy of extracorporeal shockwave treatment for knee osteoarthritis: A systematic review and meta-analysis. Exp Ther Med 2019 Oct;18(4):2843-2850.
- Li X, et al. Comparative effectiveness of extracorporeal shock wave, ultrasound, low-level laser therapy, noninvasive interactive neurostimulation, and pulsed radiofrequency treatment for treating plantar fasciitis: a systematic review and network meta-analysis. Medicine (Baltimore) 2018 Oct;97(43):e12819.

Medical Policy: EXTRACORPOREAL SHOCK WAVE THERAPY (ESWT) FOR MUSCULOSKELETAL CONDITIONS AND SOFT TISSUE WOUNDS

Policy Number: 2.01.31

Page: 6 of 8

Liao CD, et al. Efficacy of extracorporeal shock wave therapy for knee tendinopathies and other soft tissue disorders: a metaanalysis of randomized controlled trials. BMC Musculoskelet Disord 2018 Aug 2;19(1):278.

Liao CD et al. Clinical efficacy of extracorporeal shockwave therapy for knee osteoarthritis: a systematic review and meta-regression of randomized controlled trials. Clin Rehabil 2019 Sep;33(9):1419-1430.

Lizis P. Analgesic effect of extracorporeal shock wave therapy versus ultrasound therapy in chronic tennis elbow. J Phys Ther Sci 2015 Aug;27(8):2563-7.

Louwerens JK, et al. The effectiveness of high-energy extracorporeal shockwave therapy versus ultrasound-guided needling versus arthroscopic surgery in the management of chronic calcific rotator cuff tendinopathy: a systematic review. Arthroscopy 2016 Jan;32(1):165-175.

Ma H, et al. The efficacy and safety of extracorporeal shockwave therapy in knee osteoarthritis: A systematic review and meta-analysis. Int J Surg 2020 Jan 21;75:24-34.

*Malay DS, et al. Extracorporeal shockwave therapy versus placebo for the treatment of chronic proximal plantar fasciitis: results of a randomized , placebo-controlled, double-blinded, multicenter intervention trial. J Foot Ankle Surg 2006 Jul/Aug;45(4):196-210.

Mandani-Kivi M, et al. Treatment outcomes of corticosteroid injection and extracorporeal shock wave therapy as two primary therapeutic methods for acute plantar fasciitis: a prospective randomized clinical trial. J Foot Ankle Surg 2015 Nov-Dec;54(6):1047-52.

Mani-Babu S, et al. The effectiveness of extracorporeal shock wave therapy in lower limb tendinopathy: A systematic review. Am J Sports Med 2015 Mar;43(3):752-61.

Mishra BN, et al. Effectiveness of extra-corporeal shock wave therapy (ESWT) vs methylprednisolone injections in plantar fasciitis. J Clin Orthop Trauma 2019 Mar-Apr;10(2):401-405.

*National Institute for Health and Clinical Excellence. Extracorporeal shockwave therapy for refractory Achilles tendinopathy. IPG571. 2016 Dec 21[<https://www.nice.org.uk/guidance/ipg571>] accessed 2/21/20.

*National Institute for Health and Clinical Excellence. Extracorporeal shockwave therapy for refractory plantar fasciitis. IPG311. 2009 Aug 26 [<https://www.nice.org.uk/guidance/ipg311>] accessed 2/21/20.

*National Institute for Health and Clinical Excellence. Extracorporeal shockwave therapy for refractory tennis elbow. IPG313. 2009 Aug 26 [<https://www.nice.org.uk/guidance/ipg313>] accessed 2/21/20.

National Institute for Health and Clinical Excellence. Extracorporeal shockwave therapy for refractory greater trochanter pain syndrome. IPG 376. 2011 Jan 26 [<https://www.nice.org.uk/guidance/ipg376>] accessed 2/21/20.

Notarnicola A, et al. Prognostic factors of extracorporeal shock wave therapy for tendinopathies. Musculoskelet Surg 2016 Apr;100(1):53-61.

*Othman AM, et al. Endoscopic plantar fasciotomy versus extracorporeal shock wave therapy for treatment of chronic plantar fasciitis. Arch Orthop Trauma Surg 2010 Nov;130(11):1343-7.

*Ottomann C, et al. prospective randomized trial of accelerated re-epithelization of skin graft donor sites using extracorporeal shock wave therapy. J Am Coll Surg 2010 Sep;211(3):361-7.

*Ozturan KE, et al. Autologous blood and corticosteroid injection and extracorporeal shock wave therapy in the treatment of lateral epicondylitis. Orthopedics 2010 Feb 1;33(2):84-91.

*Palmier A, et al. A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shockwave therapy for the treatment of Peyronie's disease. Eur Urol 2009 Aug;56(2):363-9.

Park JW, et al. Comparison of therapeutic effect of extracorporeal shock wave in calcific versus noncalcific epicondylopathy. Ann Rehabil Med 2016 Apr;40(2):294-300.

Medical Policy: EXTRACORPOREAL SHOCK WAVE THERAPY (ESWT) FOR MUSCULOSKELETAL CONDITIONS AND SOFT TISSUE WOUNDS

Policy Number: 2.01.31

Page: 7 of 8

- Pinitkwandee S, et al. Effectiveness of extracorporeal shockwave therapy in the treatment of chronic insertional Achilles tendinopathy. Foot Ankle Int 2020 Jan 10;1071100719898461. [Epub ahead of print]
- *Pleiner J, et al. Extracorporeal shockwave treatment is effective in calcific tendonitis of the shoulder. A randomized controlled trial. Wien Klin Wochenschr 2004;116(15-16):536-41.
- *Rasmussen S, et al. Shockwave therapy for chronic Achilles tendinopathy: a double-blind, randomized clinical trial of efficacy. Acta Orthop 2008 Apr;79(2):249-56.
- Roca B, et al. Comparison of extracorporeal shock wave therapy with botulinum toxin type A in the treatment of plantar fasciitis. Disabil Rehabil 2016 Mar 1:108.
- Saggini R, et al. Clinical application of shock wave therapy in musculoskeletal disorders: part II related to myofascial and nerve apparatus. J Biol Regul Homost Agents 2015 Oct-Dec;29(4):771-85.
- *Saxena A, et al. Extra-corporeal pulse-activated therapy ("EPAT" sound wave) for Achilles tendinopathy: a prospective study. J Foot Ankle Surg 2011 May-Jun;50(3):315-9.
- Scheuer R, et al. Approaches to optimize focused extracorporeal shockwave therapy (ESWT) based on an observational study of 363 feet with recalcitrant plantar fasciitis. Int J Surg 2016 Mar;27:1-7.
- Schneider HP, et al. American College of Foot and Ankle Surgeons clinical consensus statement: diagnosis and treatment of adult acquired infracalcaneal heel pain. J Foot Ankle Surg 2018 Mar - Apr;57(2):370-381.
- *Schofer MD, et al. High-versus low-energy extracorporeal shock wave therapy of rotator cuff tendinopathy: a prospective, randomized, controlled study. Acta Orthop Belg 2009 Aug;75(4):452-8.
- Snyder R, et al. Diabetic foot ulcer treatment with focused shockwave therapy: two multicentre, prospective, controlled, doubleblinded, randomised phase III clinical trials. J Wound Care 2018 Dec 2;27(12):822-836.
- *Speed CA, et al. Extracorporeal shock wave therapy for plantar fasciitis - A double blind randomised controlled trial. J Orthop Res 2003 Sep;21(5):937-40.
- *Staples MP, et al. A randomized controlled trial of extracorporeal shock wave therapy for lateral epicondylitis (tennis elbow). J Rheumatol 2008 Oct;35(10):2038-46.
- Sun K, et al. Extracorporeal shock wave therapy versus other therapeutic methods for chronic plantar fasciitis. Foot Ankle Surg 2018 Nov 13. [Epub ahead of print]
- Taylor J, et al. Extracorporeal shockwave therapy (ESWT) for refractory Achilles tendinopathy: a prospective audit with 2-year follow up. Foot 2016 March;26:23-29.
- *Tornese D, et al. Comparison of two extracorporeal shock wave therapy techniques for the treatment of painful subcalcaneal spur. A randomized controlled study. Clin Rehabil 2008 Sep;22(9):780-7.
- U.S. Food and Drug Administration (FDA). Center for devices and radiological health CDRH. De Novo Classification request for DermaPACE System: DEN160037. 2017 Dec 28. [https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/denovo.cfm?ID=DEN160037] accessed 2/21/20.
- Verze P, et al. Efficacy and safety of low-intensity shockwave therapy plus tadalafil 5 mg once daily in men with type 2 diabetes mellitus and erectile dysfunction: a matched-pair comparison study. Asian J Androl 2019 Nov 1. [Epub ahead of print]
- *Vidal X, et al. Radial extracorporeal shock wave therapy (rESWT) in the treatment of spasticity in cerebral palsy: a randomized, placebo-controlled clinical trial. NeuroRehabilitation 2011;29(4):413-9.
- Vulpiani MC, et al. Extracorporeal shock wave therapy vs cryoultrasound therapy in the treatment of chronic lateral epicondylitis. One year follow up study. Muscles Ligaments Tendons J 2015 Oct 20;5(3):167-74.

Medical Policy: EXTRACORPOREAL SHOCK WAVE THERAPY (ESWT) FOR MUSCULOSKELETAL CONDITIONS AND SOFT TISSUE WOUNDS

Policy Number: 2.01.31

Page: 8 of 8

- Wang YC, et al. Efficacy of different energy levels used in focused and radial extracorporeal shockwave therapy in the treatment of plantar fasciitis: A meta-analysis of randomized placebo-controlled trials. J Clin Med 2019 Sep 19;8(9).
- Xiong Y, et al. Comparison of efficacy of shock-wave therapy versus corticosteroids in plantar fasciitis: a meta-analysis of randomized controlled trials. Arch Orthop Trauma Surg 2019 Apr;139(4):529-536.
- Xu Y, et al. The effect of extracorporeal shock wave therapy on the treatment of moderate to severe knee osteoarthritis and cartilage lesion. Medicine (Baltimore) 2019 May;98(20):e15523.
- Yalvaç B, et al. Comparison of ultrasound and extracorporeal shock wave therapy in lateral epicondylitis. Acta Orthop Traumatol Turc 2018 Sep;52(5):357-362.
- Yan C, et al. A comparative study of the efficacy of ultrasonics and extracorporeal shock wave in the treatment of tennis elbow: a meta-analysis of randomized controlled trials. J Orthop Surg Res 2019 Aug 6;14(1):248.
- Yu X, et al. Effectiveness of various hip preservation treatments for nontraumatic osteonecrosis of the femoral head: A network metaanalysis of randomized controlled trials. J Orthop Sci 2018 Mar;23(2):356-364.
- Zhang L, et al. Efficacy and safety of extracorporeal shock wave therapy for acute and chronic soft tissue wounds: a systematic review and meta-analysis. Int Wound J 2018 Aug;15(4):590-599.
- Zhang Q, et al. Extracorporeal shockwave therapy in osteonecrosis of femoral head: a systematic review of now available clinical evidences. Medicine 2017 Jan;96(4):e5897.
- Zhong Z, et al. A randomized controlled trial on the effects of low-dose extracorporeal shockwave therapy in patients with knee osteoarthritis. Arch Phys Med Rehabil 2019 Sep;100(9):1695-1702.
- *Zimmermann R, et al. Extracorporeal shock wave therapy for the treatment of chronic pelvic pain syndrome in males: a randomized, double-blind, placebo-controlled study. Eur Urol 2009 Sep;56(3):418-24.

*Key Article

KEY WORDS

Lithotripsy, Orthotripsy, Ossatron

CMS COVERAGE FOR MEDICARE PRODUCT MEMBERS

Based on our review, extracorporeal shock wave therapy for musculoskeletal conditions is not addressed in National or Regional Medicare coverage determinations or policies. However, there is a local coverage determination that addresses category III codes located at: https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=33392&ver=98&CntrctrSelected=298*1&Cntrctr=298&s=41&DocType=All&LCntrctr=138*1&kq=1484874194&ua=highwire&displayPDFNote=Y&bc=AggAAAQAgAAA&